Cell based immunotherapy research continues to advance and novel ideas for developing cancer therapies, such as chimeric antigen receptor (CAR-T) therapies are now a reality. Still, developing and manufacturing high-quality clinical-grade cell therapies for large scale patient use remains a challenge.
In order to bring this ground-breaking treatments to many patients as quickly as possible, researchers and manufacturers need to improve on manual, time-consuming processes. The Corning X-SERIES Cell Separation Platform is now available to simplify your cancer cell therapy workflow by offering a series of systems and technologies that can automate many of the necessary steps involved in cell processing.
This flexible multi-system platform provides a streamlined solution with speed and performance gains in purifying mononuclear cells, washing contaminants from cell fractions, selecting specific cell populations and concentrating cellular suspensions.
The Corning X-SERIES Cell Separation Platform provides a comprehensive and commercially viable, semi-automated manufacturing and controlled solution for the development of cell therapies.